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zales, the Court upheld the federal 
statute in part because “a fetus is 
a living organism within the 
womb, whether or not it is viable 
outside the womb” and “choos-
ing not to prohibit [a brutal and 
inhumane procedure] will further 
coarsen society to the humanity 
of not only newborns, but all 
vulnerable and innocent human 
life, making it increasingly diffi-
cult to protect such life.” One 
can easily imagine 
similar language in 
a decision that up-
holds prohibitions on second-tri-
mester D&E procedures or 20-week 
bans by deferring to disputed leg-
islative findings about fetal pain.
This scenario is not idle spec-
ulation. The Zika virus can have 
devastating effects on fetal devel-
opment that cannot be detected 
until well into the second trimes-
ter. If courts fail to examine the 
real motivations behind the spate 
of new laws premised on fetal 
pain and therefore uphold 20-week 
bans, anesthesia requirements, or 
procedure limitations out of judi-
cial deference to legislative find-
ings, the Whole Woman’s Health de-
cision would no longer be a whole 
women’s victory.
Disclosure forms provided by the author 
are available at NEJM.org.
From the School of Law and the Depart-
ment of Medical History and Bioethics, 
School of Medicine and Public Health, Uni-
versity of Wisconsin, Madison.
This article was published on August 10, 
2016, at NEJM.org.
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Mr. M. was hospitalized with endocarditis caused by his 
use of injected opioids. After re-
ceiving two valve replacements, 
he remained in the hospital for 
several weeks — even after his 
condition had stabilized — to 
complete a course of antibiotics, 
because there was no other op-
tion for transitional care. During 
his admission, addiction counsel-
ors recommended that he receive 
abstinence-based treatment after 
discharge. Mr. M. was not inter-
ested in such treatment, however, 
and repeatedly requested opioids 
for pain and withdrawal symp-
toms. These requests, which the 
care team interpreted as “drug-
seeking behavior” that should not 
be reinforced, caused conflicts be-
tween Mr. M. and his clinicians.
As Mr. M. began to feel better, 
he spent less time in his room 
and more time walking the halls 
and venturing outside the hospi-
tal building, arousing concern that 
he was obtaining and using illicit 
opioids. Nursing staff requested 
that hospital security conduct 
room searches, and the physician 
team asked Mr. M. to sign a be-
havioral contract promising to re-
frain from illicit drug use.
After discharge, Mr. M. did 
not keep his follow-up appoint-
ments, continued to inject opioids, 
and was admitted months later 
with prosthetic-valve endocarditis. 
Though a repeat valve-replacement 
procedure was performed, he died 
from complications of endocardi-
tis after another prolonged hos-
pitalization.
This unfortunate outcome was 
not entirely unexpected. The risk 
of death or reoperation between 
90 and 180 days after an index 
surgery for endocarditis is 10 times 
as high among persons who inject 
drugs as among those who do 
not.1 These outcomes probably re-
flect inadequately treated addic-
tion, ongoing injection-drug use, 
and potential overdose. It is pre-
mature to argue that treating 
such patients for infections is 
medically futile and wasteful of 
resources when their underlying 
opioid-use disorder (OUD) has not 
yet been treated in an evidence-
based manner. Typically, the focus 
of the hospitalization is on man-
aging the infection,2 and common 
interventions related to OUD, such 
as restricting pain medications 
and the patient’s mobility, not only 
erode the doctor–patient relation-
ship but are also ineffective. This 
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dynamic, along with undertreated 
pain and opioid withdrawal, prob-
ably contributes to the high rates 
of discharge against medical ad-
vice (11 to 12%) among hospital-
ized patients with OUD.3
Hospitalizations for severe in-
fections associated with OUD, 
such as endocarditis and osteo-
myelitis, have doubled in the 
United States over the past decade 
and are frequently prolonged and 
resource-intensive.3 Once their con-
dition has stabilized, most patients 
with such infections complete in-
travenous antibiotic therapy either 
at home with home health sup-
port or in a postacute care facility. 
But patients with medically and 
psychosocially complex condi-
tions, such as OUD, are often 
denied admission to skilled nurs-
ing facilities,3 and residential 
addiction-treatment programs are 
generally not equipped to man-
age coexisting medical illnesses. 
These constraints, coupled with 
concerns that such patients will 
continue to use injected opioids 
and will fail to adhere to an anti-
biotic regimen after discharge, 
mean that they often remain in 
the hospital for weeks while re-
ceiving intravenous antibiotics.3 
This costly clinical choice is in-
tended to be the safest option; 
however, without simultaneous 
treatment of OUD — the under-
lying cause of the infection — a 
host of other problems ensue.
We believe there is an urgent 
need to integrate evidence-based 
medication-assisted treatment 
(MAT) for OUD — naltrexone, 
buprenorphine, or methadone 
therapy — into hospital care. 
MAT has been shown to reduce 
illicit opioid use and related mor-
bidity and mortality.4 In addition, 
methadone and buprenorphine 
help in managing pain and with-
drawal, which could reduce clini-
cian–patient conflict, help engage 
patients in care, and reduce the 
number of discharges that occur 
against medical advice. Research 
has shown that buprenorphine 
treatment for OUD can be initiat-
ed successfully in acute care set-
tings such as emergency depart-
ments and then continued on an 
outpatient basis.5
Since relapse rates without 
MAT (in detoxification or absti-
nence-only programs) exceed 80%,4 
it seems logical to initiate MAT 
during hospitalization — though 
doing so won’t be easy. The many 
barriers include the limited avail-
ability of outpatient buprenor-
phine providers and licensed 
methadone clinics, as well as dif-
ficulties with insurance coverage. 
Furthermore, stringent federal pri-
vacy regulations specific to the 
treatment of substance-use dis-
order, though intended to protect 
patients, effectively segregate such 
treatment from general medical 
care, thereby impeding the devel-
opment of integrated care systems.
Implementing evidence-based 
care for hospitalized patients with 
OUD may substantially improve 
outcomes and reduce costs. A 
reasonable first step is to ensure 
that all patients admitted to the 
hospital with an opioid overdose, 
or a medical illness with con-
comitant opioid use, receive a 
comprehensive assessment for 
substance-use disorder. If there 
is a current diagnosis of OUD, 
we believe that informed consent 
and initiation of MAT for OUD 
should be a priority.
Some patients may not want 
to accept MAT even if it is recom-
mended, but health care provid-
ers can still apply harm-reduction 
practices such as standardized 
treatment of pain and withdrawal 
during hospitalization; education 
of patients and families about 
how to inject safely, how to ob-
tain clean needles, and how to 
avoid, recognize, and treat opioid 
overdose; and provision at dis-
charge of prescriptions for intra-
nasal naloxone. These simple ac-
tions can reduce morbidity and 
mortality and communicate that 
the health care community is in-
vested in treating and minimiz-
ing complications of OUD. Dem-
onstrating with our actions that 
we know OUD is an illness rath-
er than a moral failing is critical 
for patients. That message differs 
greatly from the one that was 
sent to Mr. M.
Clinical research is also ur-
gently needed. People who inject 
drugs have been excluded from 
studies of outpatient parenteral 
antibiotic therapy — an omission 
that leaves providers without an 
evidence base to support ambula-
tory transitional management of 
infections. There are no data to 
suggest that keeping these patients 
in the hospital affects rates of 
completion of antibiotic treatment 
or of reoperation or that doing 
so prevents illicit drug use. There 
may in fact be harm associated 
with prolonged hospitalization, 
such as increased risk of opioid 
overdose because of reduced physi-
ological tolerance after weeks of 
relative opioid abstinence in the 
hospital; there are reports of fa-
tal overdoses after people who 
inject drugs leave jails or detox 
programs.
Additional research is needed 
to better define the underlying 
substance-use disorders, motiva-
tions for treatment, and available 
social support to help guide treat-
ment of patients admitted to the 
hospital with infections and OUD. 
We must also effectively address 
the treatment of pain, an often 
complex but essential aspect of 
care, if we are to keep patients 
engaged. Perhaps patients who 
are highly motivated, are ac-
cepting of MAT, and have social 
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support to assist with ongoing 
medical treatment would be can-
didates for innovative transitional 
care programs aimed at support-
ing remission of OUD, avoiding 
reinfection, and reducing costs.
The unfortunate case of Mr. M. 
highlights the fact that the cur-
rent approach to hospitalized pa-
tients with OUD and infections 
is far from optimal. Hospitals 
will have to be part of any com-
prehensive plan to address the 
opioid epidemic. Currently, we are 
not routinely assessing the sever-
ity or treatment needs of the un-
derlying OUD, initiating evidence-
based treatments, and supporting 
risk reduction. Though OUD is a 
complex medical illness amena-
ble to treatment, stigma and con-
flict unfortunately continue to 
influence care, frustrate providers, 
and marginalize patients.
The Affordable Care Act man-
dates parity between treatment of 
substance-use disorders and that 
of other medical illnesses, and the 
American Board of Medical Spe-
cialties now recognizes addiction 
medicine as a medical subspecial-
ty. Since there are not enough 
trained addiction medicine physi-
cians to curb the opioid epidem-
ic, we believe education about 
evidence-based OUD treatment 
should be expanded to all mem-
bers of the care team and inte-
grated into standard hospital care. 
Education coupled with expanded 
treatment resources can improve 
patients’ experience, increase ad-
herence to treatment recommen-
dations, and improve health out-
comes. It is time to put parity 
into practice.
Disclosure forms provided by the authors 
are available at NEJM.org.
From the Center for Health Services Re-
search (L.F.) and the Center on Drug and 
Alcohol Research (M.R.L.), University of 
Kentucky College of Medicine, Lexington.
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Arthur R. Williams, M.D., M.B.E., and Adam Bisaga, M.D. 
The United States is facing a vast epidemic of opioid-related 
deaths. More than 2.4 million 
Americans have a severe opioid-
use disorder (OUD) involving de-
pendence on pain medications, 
heroin, or both, and rates of drug-
overdose deaths in this country 
have outpaced mortality from mo-
tor vehicle accidents since 2013. 
The rising death toll has been 
rivaled in modern history only by 
that at the peak of the AIDS epi-
demic in the early 1990s. Although 
these epidemics differ in nature, 
the large-scale, highly coordinated 
response to AIDS that was even-
tually mounted may be instruc-
tive for combating the opioid epi-
demic.
In the face of growing alarm 
in communities nationwide, the 
U.S. Senate recently passed the 
Comprehensive Addiction and Re-
covery Act (CARA), which takes 
incremental steps to combat the 
epidemic. President Barack Obama 
signed it into law in July, despite 
the fact that Congress withheld 
funding. In his 2017 budget pro-
posal, Obama had incorporated 
$1.1 billion for expanding access 
to evidence-based care, includ-
ing medication-assisted treatment 
(MAT) using methadone, bupre-
norphine, or injectable naltrexone. 
Funding would be targeted to 
hardest-hit states and those pro-
posing the most promising inter-
ventions for getting needed treat-
ment to people with OUD.
Funding is critically impor-
tant and long overdue — but will 
be insufficient without structural 
changes, revised regulations, and 
improved services to help connect 
marginalized populations with 
programs and providers that use 
modern, science-based approaches 
to treat OUD as a chronic medi-
cal condition. Despite the exis-
tence of pharmacologic and be-
havioral treatments based on a 
generation of research, most treat-
ment programs do not offer evi-
dence-based care and have mini-
mal physician involvement.1,2 The 
substance-abuse treatment system 
(programs accredited by the Sub-
stance Abuse and Mental Health 
Services Administration) has thus 
far struggled to implement prac-
tices based on science. Too often, 
treatment centers operate under 
outdated institutional ideologies 
favoring abstinence-only approach-
The New England Journal of Medicine 
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